| Annual Financials | Mar 2025 | Mar 2026 |
| Revenue | 49.27 | 52.51 |
| Expenses | 41.89 | 44.66 |
| Other Income | 0.05 | 0.08 |
| Total Revenue | 49.32 | 52.59 |
| Profit Before Tax | 7.43 | 7.93 |
| Net Profit | 5.35 | 5.64 |


The company is led by qualified and experienced management team including U.S.-trained doctors with extensive expertise in their respective clinical specialties, bringing decades of healthcare experience and international standards to operations.
The company prioritizes attracting and retaining renowned clinicians with over 30% of doctors associated for more than 5 years, including team members trained at institutes in India and overseas with full-time commitment.
The company offers medical services across 25 specialties covering comprehensive healthcare needs, with diversified revenue streams reducing concentration risks and serving as a one-stop solution for routine and complex medical conditions.
The company was incorporated in March 2021 and acquired the business of M/s. Anil Baghi Hospital in March 2022, resulting in limited operating and financial history. This makes it difficult to evaluate current or future prospects based on historical results, and future revenues and profitability could fluctuate significantly.
The company derives 100% of its revenue from its only hospital in Ferozepur, Punjab (₹5,104.37 lakhs in Fiscal 2026 and ₹4,891.62 lakhs in Fiscal 2025). Any adverse event affecting this single location could have a material impact on business operations and financial condition.
The company faces risks from technological changes, equipment failures, and malfunction of medical equipment. The company incurred ₹396.23 lakhs, ₹142.39 lakhs, and ₹889.51 lakhs for equipment additions in Fiscal 2026, 2025, and 2024 respectively, with potential for asset impairment.
The company proposes to utilize funds from the Net Proceeds towards repayment/prepayment, in part or full, of certain borrowings to reduce outstanding indebtedness, debt servicing costs, and improve debt-to-equity ratio.
The company proposes to utilize funds from the Net Proceeds towards funding its working capital requirements to support future growth requirements and business operations.
The company expects to utilize funds from the Net Proceeds towards funding inorganic growth through unidentified acquisitions and general corporate purposes, subject to regulatory limits under SEBI ICDR Regulations.
| Annual Financials | Mar 2025 | Mar 2026 |
| Revenue | 49.27 | 52.51 |
| Expenses | 41.89 | 44.66 |
| Other Income | 0.05 | 0.08 |
| Total Revenue | 49.32 | 52.59 |
| Profit Before Tax | 7.43 | 7.93 |
| Net Profit | 5.35 | 5.64 |
| Balance Sheet | Mar 2025 | Mar 2026 |
| Total Assets | 63.90 | 85.27 |
| Current Assets | 26.62 | 41.54 |
| Fixed Assets | 37.29 | 43.73 |
| Total Equity & Liabilities | 63.90 | 85.27 |
| Total Liabilities | 52.20 | 67.93 |
| Current Liabilities | 21.15 | 14.14 |
| Non Current Liabilities | 31.05 | 53.79 |
| Total Equity | 11.69 | 17.34 |
| Cash Flow | Mar 2025 | Mar 2026 |
| Net Cash Flow | 0.59 | 2.42 |
| Investing Activities | -4.53 | -9.14 |
| Operating Activities | 3.54 | 2.11 |
| Financing Activities | 1.58 | 9.45 |